ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Myostatin Inhibitors Muscle-Building Potential
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 25049" data-attributes="member: 3"><p>Scholar Rock, a small startup located in Cambridge, Massachusetts, revealed new data regarding lead drug candidate SRK-015 last week at the European Molecular Biology Organization’s annual meeting. </p><p></p><p>The compound is a “niche modulator inhibiting activation of the latent myostatin precursor,” explains the company’s announcement.</p><p></p><p>As NPR reports, myostatin is a type of protein that plays a role in suppressing muscle growth leading to diseases like muscular dystrophy or similar muscle-wasting conditions as a result of cancer, or even old age. </p><p></p><p>Preclinical data demonstrated SRK-015 was able to systematically block myostatin activation in vitro and was able to augment muscle strength in vitro while avoiding “undesirable” side effects, according to Scholar Rock’s statement.</p><p></p><p><a href="http://www.dddmag.com/news/2015/09/scholar-rock-touts-muscle-building-drugs-potential?et_cid=4843618&et_rid=449166332&type=headline" target="_blank">http://www.dddmag.com/news/2015/09/scholar-rock-touts-muscle-building-drugs-potential?et_cid=4843618&et_rid=449166332&type=headline</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 25049, member: 3"] Scholar Rock, a small startup located in Cambridge, Massachusetts, revealed new data regarding lead drug candidate SRK-015 last week at the European Molecular Biology Organization’s annual meeting. The compound is a “niche modulator inhibiting activation of the latent myostatin precursor,” explains the company’s announcement. As NPR reports, myostatin is a type of protein that plays a role in suppressing muscle growth leading to diseases like muscular dystrophy or similar muscle-wasting conditions as a result of cancer, or even old age. Preclinical data demonstrated SRK-015 was able to systematically block myostatin activation in vitro and was able to augment muscle strength in vitro while avoiding “undesirable” side effects, according to Scholar Rock’s statement. [url]http://www.dddmag.com/news/2015/09/scholar-rock-touts-muscle-building-drugs-potential?et_cid=4843618&et_rid=449166332&type=headline[/url] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Myostatin Inhibitors Muscle-Building Potential
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top